Natalie S Callander
ECOG-ACRIN Cancer Research Group · University of Wisconsin, Madison · UWCCC
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Natalie S Callander as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:51 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT03937635 · Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaECOG-ACRIN Cancer Research Group · recruiting · Smoldering Plasma Cell Myeloma · principal investigator
- Ph1NCT02278315 · Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple MyelomaCellectar Biosciences, Inc. · completed · Multiple Myeloma · principal investigator
- Ph2NCT00581919 · Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple MyelomaUniversity of Wisconsin, Madison · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT03937635
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 11:51 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- Lenalidomide after stem-cell transplantation for multiple myeloma.N Engl J Med · 2012918 citationsRCR 24.3
- 827 citationsRCR 21.0
- Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.J Clin Oncol · 2022234 citationsRCR 18.1
- Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.Lancet Haematol · 2023157 citationsRCR 14.3
- 151 citationsRCR 4.7
- 74 citationsRCR 2.3
- Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).Blood Cancer J · 202171 citationsRCR 3.7
- Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.Br J Cancer · 202240 citationsRCR 2.7
- Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.Blood Cancer J · 202435 citationsRCR 4.3
- 33 citationsRCR 0.8